nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—systemic scleroderma—systemic lupus erythematosus	0.378	0.565	CtDrD
Leflunomide—rheumatoid arthritis—systemic lupus erythematosus	0.291	0.435	CtDrD
Leflunomide—ABCG2—Mycophenolate mofetil—systemic lupus erythematosus	0.0358	0.23	CbGbCtD
Leflunomide—ABCG2—Hydrocortisone—systemic lupus erythematosus	0.0288	0.184	CbGbCtD
Leflunomide—ABCG2—Cyclosporine—systemic lupus erythematosus	0.0272	0.174	CbGbCtD
Leflunomide—ABCG2—Dexamethasone—systemic lupus erythematosus	0.0179	0.115	CbGbCtD
Leflunomide—CYP2C9—Dapsone—systemic lupus erythematosus	0.0154	0.0984	CbGbCtD
Leflunomide—ABCG2—Methotrexate—systemic lupus erythematosus	0.0144	0.0921	CbGbCtD
Leflunomide—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.0101	0.0646	CbGbCtD
Leflunomide—CYP2C9—cardial valve—systemic lupus erythematosus	0.00682	0.2	CbGeAlD
Leflunomide—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.00664	0.0426	CbGbCtD
Leflunomide—PTK2B—blood plasma—systemic lupus erythematosus	0.00264	0.0774	CbGeAlD
Leflunomide—DHODH—skin of body—systemic lupus erythematosus	0.002	0.0588	CbGeAlD
Leflunomide—DHODH—lymphoid tissue—systemic lupus erythematosus	0.00162	0.0476	CbGeAlD
Leflunomide—CYP1A2—urine—systemic lupus erythematosus	0.00155	0.0455	CbGeAlD
Leflunomide—DHODH—tendon—systemic lupus erythematosus	0.00152	0.0447	CbGeAlD
Leflunomide—CYP2C9—urine—systemic lupus erythematosus	0.00147	0.0432	CbGeAlD
Leflunomide—PTK2B—connective tissue—systemic lupus erythematosus	0.0014	0.0412	CbGeAlD
Leflunomide—DHODH—lung—systemic lupus erythematosus	0.00134	0.0393	CbGeAlD
Leflunomide—PTK2B—kidney—systemic lupus erythematosus	0.0012	0.0351	CbGeAlD
Leflunomide—AHR—nephron tubule—systemic lupus erythematosus	0.00112	0.0328	CbGeAlD
Leflunomide—PTK2B—lymphoid tissue—systemic lupus erythematosus	0.00103	0.0301	CbGeAlD
Leflunomide—PTK2B—tendon—systemic lupus erythematosus	0.000965	0.0283	CbGeAlD
Leflunomide—AHR—cortex of kidney—systemic lupus erythematosus	0.000957	0.0281	CbGeAlD
Leflunomide—PTK2B—bone marrow—systemic lupus erythematosus	0.000935	0.0275	CbGeAlD
Leflunomide—PTK2B—lung—systemic lupus erythematosus	0.000847	0.0249	CbGeAlD
Leflunomide—CYP1A2—blood plasma—systemic lupus erythematosus	0.000809	0.0238	CbGeAlD
Leflunomide—AHR—tendon—systemic lupus erythematosus	0.000793	0.0233	CbGeAlD
Leflunomide—PTK2B—nervous system—systemic lupus erythematosus	0.000784	0.023	CbGeAlD
Leflunomide—AHR—bone marrow—systemic lupus erythematosus	0.000768	0.0226	CbGeAlD
Leflunomide—CYP2C9—blood plasma—systemic lupus erythematosus	0.000768	0.0226	CbGeAlD
Leflunomide—PTK2B—central nervous system—systemic lupus erythematosus	0.000755	0.0222	CbGeAlD
Leflunomide—AHR—lung—systemic lupus erythematosus	0.000696	0.0204	CbGeAlD
Leflunomide—ABCG2—nephron tubule—systemic lupus erythematosus	0.000434	0.0127	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—systemic lupus erythematosus	0.000378	1	CrCbGaD
Leflunomide—ABCG2—bone marrow—systemic lupus erythematosus	0.000298	0.00875	CbGeAlD
Leflunomide—ABCG2—lung—systemic lupus erythematosus	0.00027	0.00793	CbGeAlD
Leflunomide—CYP1A2—lung—systemic lupus erythematosus	0.00026	0.00763	CbGeAlD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP9—systemic lupus erythematosus	0.000208	0.00549	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—JAK1—systemic lupus erythematosus	0.000206	0.00544	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—NCF2—systemic lupus erythematosus	0.000204	0.00537	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—CSK—systemic lupus erythematosus	0.000203	0.00534	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—TYK2—systemic lupus erythematosus	0.00019	0.005	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—systemic lupus erythematosus	0.000187	0.00492	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD8A—systemic lupus erythematosus	0.000178	0.00468	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—PPARG—systemic lupus erythematosus	0.000175	0.00461	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—IL2—systemic lupus erythematosus	0.000173	0.00455	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—ETS1—systemic lupus erythematosus	0.000172	0.00454	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CCR5—systemic lupus erythematosus	0.000162	0.00428	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CCL2—systemic lupus erythematosus	0.000161	0.00425	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—FAS—systemic lupus erythematosus	0.000161	0.00424	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—IFNG—systemic lupus erythematosus	0.000159	0.00419	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL2—systemic lupus erythematosus	0.000158	0.00416	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL18—systemic lupus erythematosus	0.000156	0.00411	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—FAS—systemic lupus erythematosus	0.000154	0.00407	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—HLA-DRB1—systemic lupus erythematosus	0.000153	0.00403	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—JAK1—systemic lupus erythematosus	0.000149	0.00393	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—JAK1—systemic lupus erythematosus	0.000148	0.00391	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1B—systemic lupus erythematosus	0.000146	0.00386	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TYK2—systemic lupus erythematosus	0.000146	0.00386	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—IL2—systemic lupus erythematosus	0.000141	0.00372	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CXCL12—systemic lupus erythematosus	0.000141	0.00372	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—JAK1—systemic lupus erythematosus	0.000141	0.00371	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic lupus erythematosus	0.000139	0.00365	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL2RA—systemic lupus erythematosus	0.000138	0.00365	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1A—systemic lupus erythematosus	0.000135	0.00356	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MMP9—systemic lupus erythematosus	0.000134	0.00352	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRF5—systemic lupus erythematosus	0.000129	0.00339	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—CDKN1B—systemic lupus erythematosus	0.000128	0.00336	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CDKN1B—systemic lupus erythematosus	0.000124	0.00328	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—PPARG—systemic lupus erythematosus	0.000123	0.00325	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRF8—systemic lupus erythematosus	0.000123	0.00324	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CDKN1A—systemic lupus erythematosus	0.00012	0.00317	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—LYN—systemic lupus erythematosus	0.000119	0.00313	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP9—systemic lupus erythematosus	0.000117	0.00308	CbGpPWpGaD
Leflunomide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000109	0.00289	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CD4—systemic lupus erythematosus	0.000108	0.00284	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—JAK1—systemic lupus erythematosus	0.000107	0.00282	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NAT2—systemic lupus erythematosus	0.000106	0.00281	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—systemic lupus erythematosus	0.000106	0.0028	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—systemic lupus erythematosus	0.000104	0.00275	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—systemic lupus erythematosus	0.000103	0.00273	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD4—systemic lupus erythematosus	0.000102	0.00269	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EP300—systemic lupus erythematosus	0.000101	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1RN—systemic lupus erythematosus	0.000101	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—systemic lupus erythematosus	9.98e-05	0.00263	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TGFB1—systemic lupus erythematosus	9.94e-05	0.00262	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—TYK2—systemic lupus erythematosus	9.82e-05	0.00259	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TREX1—systemic lupus erythematosus	9.81e-05	0.00259	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—TYK2—systemic lupus erythematosus	9.75e-05	0.00257	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NOS3—systemic lupus erythematosus	9.64e-05	0.00254	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—systemic lupus erythematosus	9.6e-05	0.00253	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	9.45e-05	0.00249	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MMP9—systemic lupus erythematosus	9.39e-05	0.00247	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TNF—systemic lupus erythematosus	9.28e-05	0.00245	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL6—systemic lupus erythematosus	9.28e-05	0.00245	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—TYK2—systemic lupus erythematosus	9.27e-05	0.00244	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNA1—systemic lupus erythematosus	9.15e-05	0.00241	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NOS3—systemic lupus erythematosus	9.1e-05	0.0024	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C1S—systemic lupus erythematosus	8.74e-05	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TRIM21—systemic lupus erythematosus	8.74e-05	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C1R—systemic lupus erythematosus	8.74e-05	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RASGRP3—systemic lupus erythematosus	8.74e-05	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR10—systemic lupus erythematosus	8.74e-05	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PRL—systemic lupus erythematosus	8.64e-05	0.00228	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—EP300—systemic lupus erythematosus	8.53e-05	0.00225	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	8.43e-05	0.00222	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DQA1—systemic lupus erythematosus	8.2e-05	0.00216	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL2—systemic lupus erythematosus	8.11e-05	0.00214	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	8.1e-05	0.00213	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—systemic lupus erythematosus	8.08e-05	0.00213	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	8.07e-05	0.00213	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—EP300—systemic lupus erythematosus	8.07e-05	0.00213	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	7.99e-05	0.0021	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DQB1—systemic lupus erythematosus	7.67e-05	0.00202	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IL6—systemic lupus erythematosus	7.49e-05	0.00197	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD226—systemic lupus erythematosus	7.43e-05	0.00196	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KLRK1—systemic lupus erythematosus	7.43e-05	0.00196	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—NAT2—systemic lupus erythematosus	7.43e-05	0.00196	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—systemic lupus erythematosus	7.32e-05	0.00193	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL18—systemic lupus erythematosus	7.27e-05	0.00192	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—systemic lupus erythematosus	7.25e-05	0.00191	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR5—systemic lupus erythematosus	6.99e-05	0.00184	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—systemic lupus erythematosus	6.94e-05	0.00183	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—NOS3—systemic lupus erythematosus	6.92e-05	0.00182	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—JAK1—systemic lupus erythematosus	6.91e-05	0.00182	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FCGR2B—systemic lupus erythematosus	6.8e-05	0.00179	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C1QA—systemic lupus erythematosus	6.63e-05	0.00175	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—UBE2L3—systemic lupus erythematosus	6.63e-05	0.00175	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	6.62e-05	0.00175	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	6.58e-05	0.00174	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—systemic lupus erythematosus	6.56e-05	0.00173	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2RA—systemic lupus erythematosus	6.46e-05	0.0017	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C4B—systemic lupus erythematosus	6.32e-05	0.00167	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C4A—systemic lupus erythematosus	6.32e-05	0.00167	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR7—systemic lupus erythematosus	6.06e-05	0.0016	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PDCD1—systemic lupus erythematosus	6.06e-05	0.0016	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—RXRA—systemic lupus erythematosus	5.97e-05	0.00157	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—XRCC6—systemic lupus erythematosus	5.94e-05	0.00157	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DRB1—systemic lupus erythematosus	5.83e-05	0.00154	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	5.66e-05	0.00149	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CR1—systemic lupus erythematosus	5.63e-05	0.00149	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	5.63e-05	0.00148	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL6—systemic lupus erythematosus	5.52e-05	0.00145	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR6—systemic lupus erythematosus	5.37e-05	0.00142	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CFB—systemic lupus erythematosus	5.37e-05	0.00142	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	5.37e-05	0.00141	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—IL6—systemic lupus erythematosus	5.28e-05	0.00139	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—NAT2—systemic lupus erythematosus	5.09e-05	0.00134	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FCGR3A—systemic lupus erythematosus	5.02e-05	0.00132	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	5.02e-05	0.00132	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	5.02e-05	0.00132	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RIPK1—systemic lupus erythematosus	4.96e-05	0.00131	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6—systemic lupus erythematosus	4.8e-05	0.00127	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR9—systemic lupus erythematosus	4.79e-05	0.00126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL6—systemic lupus erythematosus	4.77e-05	0.00126	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	4.75e-05	0.00125	CbGpPWpGaD
Leflunomide—Pain—Prednisolone—systemic lupus erythematosus	4.72e-05	0.000462	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—systemic lupus erythematosus	4.71e-05	0.000461	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—systemic lupus erythematosus	4.71e-05	0.000461	CcSEcCtD
Leflunomide—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	4.7e-05	0.00046	CcSEcCtD
Leflunomide—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	4.68e-05	0.000458	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—systemic lupus erythematosus	4.68e-05	0.000458	CcSEcCtD
Leflunomide—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	4.67e-05	0.000457	CcSEcCtD
Leflunomide—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	4.67e-05	0.000457	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	4.66e-05	0.000456	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	4.65e-05	0.000455	CcSEcCtD
Leflunomide—Fatigue—Hydrocortisone—systemic lupus erythematosus	4.64e-05	0.000455	CcSEcCtD
Leflunomide—Vision blurred—Prednisone—systemic lupus erythematosus	4.63e-05	0.000453	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—systemic lupus erythematosus	4.62e-05	0.000452	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	4.62e-05	0.000452	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	4.61e-05	0.000451	CcSEcCtD
Leflunomide—Pain—Hydrocortisone—systemic lupus erythematosus	4.61e-05	0.000451	CcSEcCtD
Leflunomide—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	4.6e-05	0.00045	CcSEcCtD
Leflunomide—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	4.6e-05	0.00045	CcSEcCtD
Leflunomide—Insomnia—Triamcinolone—systemic lupus erythematosus	4.59e-05	0.000449	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	4.59e-05	0.00121	CbGpPWpGaD
Leflunomide—Insomnia—Methylprednisolone—systemic lupus erythematosus	4.58e-05	0.000448	CcSEcCtD
Leflunomide—Infection—Betamethasone—systemic lupus erythematosus	4.57e-05	0.000447	CcSEcCtD
Leflunomide—Infection—Dexamethasone—systemic lupus erythematosus	4.57e-05	0.000447	CcSEcCtD
Leflunomide—Ill-defined disorder—Prednisone—systemic lupus erythematosus	4.56e-05	0.000446	CcSEcCtD
Leflunomide—Paraesthesia—Triamcinolone—systemic lupus erythematosus	4.55e-05	0.000446	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—TYK2—systemic lupus erythematosus	4.55e-05	0.0012	CbGpPWpGaD
Leflunomide—Feeling abnormal—Prednisolone—systemic lupus erythematosus	4.54e-05	0.000445	CcSEcCtD
Leflunomide—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	4.54e-05	0.000445	CcSEcCtD
Leflunomide—Anaemia—Prednisone—systemic lupus erythematosus	4.54e-05	0.000444	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—IL6—systemic lupus erythematosus	4.53e-05	0.0012	CbGpPWpGaD
Leflunomide—Dyspnoea—Triamcinolone—systemic lupus erythematosus	4.52e-05	0.000443	CcSEcCtD
Leflunomide—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	4.51e-05	0.000442	CcSEcCtD
Leflunomide—Nervous system disorder—Betamethasone—systemic lupus erythematosus	4.51e-05	0.000442	CcSEcCtD
Leflunomide—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	4.51e-05	0.000441	CcSEcCtD
Leflunomide—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	4.51e-05	0.000441	CcSEcCtD
Leflunomide—Tachycardia—Betamethasone—systemic lupus erythematosus	4.49e-05	0.00044	CcSEcCtD
Leflunomide—Tachycardia—Dexamethasone—systemic lupus erythematosus	4.49e-05	0.00044	CcSEcCtD
Leflunomide—Angioedema—Prednisone—systemic lupus erythematosus	4.49e-05	0.000439	CcSEcCtD
Leflunomide—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	4.47e-05	0.000437	CcSEcCtD
Leflunomide—Dyspepsia—Triamcinolone—systemic lupus erythematosus	4.46e-05	0.000437	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—systemic lupus erythematosus	4.46e-05	0.000436	CcSEcCtD
Leflunomide—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	4.45e-05	0.000436	CcSEcCtD
Leflunomide—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	4.45e-05	0.000435	CcSEcCtD
Leflunomide—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	4.45e-05	0.000435	CcSEcCtD
Leflunomide—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	4.44e-05	0.000434	CcSEcCtD
Leflunomide—Malaise—Prednisone—systemic lupus erythematosus	4.43e-05	0.000433	CcSEcCtD
Leflunomide—Vertigo—Prednisone—systemic lupus erythematosus	4.41e-05	0.000432	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—systemic lupus erythematosus	4.41e-05	0.000431	CcSEcCtD
Leflunomide—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	4.4e-05	0.000431	CcSEcCtD
Leflunomide—Anorexia—Betamethasone—systemic lupus erythematosus	4.39e-05	0.000429	CcSEcCtD
Leflunomide—Anorexia—Dexamethasone—systemic lupus erythematosus	4.39e-05	0.000429	CcSEcCtD
Leflunomide—Urticaria—Prednisolone—systemic lupus erythematosus	4.38e-05	0.000429	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—systemic lupus erythematosus	4.38e-05	0.000428	CcSEcCtD
Leflunomide—Fatigue—Triamcinolone—systemic lupus erythematosus	4.37e-05	0.000428	CcSEcCtD
Leflunomide—Fatigue—Methylprednisolone—systemic lupus erythematosus	4.36e-05	0.000427	CcSEcCtD
Leflunomide—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	4.36e-05	0.000426	CcSEcCtD
Leflunomide—Asthenia—Cyclosporine—systemic lupus erythematosus	4.35e-05	0.000426	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—NAT2—systemic lupus erythematosus	4.35e-05	0.00115	CbGpPWpGaD
Leflunomide—Pain—Triamcinolone—systemic lupus erythematosus	4.34e-05	0.000424	CcSEcCtD
Leflunomide—Hypotension—Betamethasone—systemic lupus erythematosus	4.3e-05	0.000421	CcSEcCtD
Leflunomide—Hypotension—Dexamethasone—systemic lupus erythematosus	4.3e-05	0.000421	CcSEcCtD
Leflunomide—Pruritus—Cyclosporine—systemic lupus erythematosus	4.29e-05	0.00042	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—NAT2—systemic lupus erythematosus	4.29e-05	0.00113	CbGpPWpGaD
Leflunomide—Urticaria—Hydrocortisone—systemic lupus erythematosus	4.28e-05	0.000419	CcSEcCtD
Leflunomide—PTK2B—Immune System—CSK—systemic lupus erythematosus	4.27e-05	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNG—systemic lupus erythematosus	4.26e-05	0.00112	CbGpPWpGaD
Leflunomide—Immune system disorder—Methotrexate—systemic lupus erythematosus	4.26e-05	0.000417	CcSEcCtD
Leflunomide—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	4.26e-05	0.000417	CcSEcCtD
Leflunomide—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	4.26e-05	0.000417	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	4.25e-05	0.000416	CcSEcCtD
Leflunomide—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	4.24e-05	0.000415	CcSEcCtD
Leflunomide—Hypertension—Prednisone—systemic lupus erythematosus	4.24e-05	0.000415	CcSEcCtD
Leflunomide—PTK2B—Immune System—MBL2—systemic lupus erythematosus	4.23e-05	0.00112	CbGpPWpGaD
Leflunomide—Chills—Methotrexate—systemic lupus erythematosus	4.23e-05	0.000414	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRF5—systemic lupus erythematosus	4.2e-05	0.00111	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	4.19e-05	0.00041	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	4.19e-05	0.00041	CcSEcCtD
Leflunomide—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	4.18e-05	0.000409	CcSEcCtD
Leflunomide—Myalgia—Prednisone—systemic lupus erythematosus	4.18e-05	0.000409	CcSEcCtD
Leflunomide—Arthralgia—Prednisone—systemic lupus erythematosus	4.18e-05	0.000409	CcSEcCtD
Leflunomide—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	4.18e-05	0.000409	CcSEcCtD
Leflunomide—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	4.17e-05	0.000408	CcSEcCtD
Leflunomide—Anxiety—Prednisone—systemic lupus erythematosus	4.17e-05	0.000408	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—systemic lupus erythematosus	4.17e-05	0.000408	CcSEcCtD
Leflunomide—Insomnia—Betamethasone—systemic lupus erythematosus	4.16e-05	0.000407	CcSEcCtD
Leflunomide—Insomnia—Dexamethasone—systemic lupus erythematosus	4.16e-05	0.000407	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	4.15e-05	0.000406	CcSEcCtD
Leflunomide—Diarrhoea—Cyclosporine—systemic lupus erythematosus	4.15e-05	0.000406	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	4.14e-05	0.000405	CcSEcCtD
Leflunomide—Paraesthesia—Betamethasone—systemic lupus erythematosus	4.13e-05	0.000404	CcSEcCtD
Leflunomide—Paraesthesia—Dexamethasone—systemic lupus erythematosus	4.13e-05	0.000404	CcSEcCtD
Leflunomide—Discomfort—Prednisone—systemic lupus erythematosus	4.13e-05	0.000404	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—systemic lupus erythematosus	4.13e-05	0.000404	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—systemic lupus erythematosus	4.1e-05	0.000402	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisolone—systemic lupus erythematosus	4.06e-05	0.000398	CcSEcCtD
Leflunomide—Dyspepsia—Dexamethasone—systemic lupus erythematosus	4.05e-05	0.000396	CcSEcCtD
Leflunomide—Dyspepsia—Betamethasone—systemic lupus erythematosus	4.05e-05	0.000396	CcSEcCtD
Leflunomide—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	4.05e-05	0.000396	CcSEcCtD
Leflunomide—Urticaria—Triamcinolone—systemic lupus erythematosus	4.03e-05	0.000394	CcSEcCtD
Leflunomide—Urticaria—Methylprednisolone—systemic lupus erythematosus	4.02e-05	0.000393	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—systemic lupus erythematosus	4.02e-05	0.000393	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRF8—systemic lupus erythematosus	4.01e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD247—systemic lupus erythematosus	4.01e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ITGAM—systemic lupus erythematosus	4.01e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFIH1—systemic lupus erythematosus	4.01e-05	0.00106	CbGpPWpGaD
Leflunomide—Body temperature increased—Triamcinolone—systemic lupus erythematosus	4.01e-05	0.000392	CcSEcCtD
Leflunomide—Dizziness—Cyclosporine—systemic lupus erythematosus	4.01e-05	0.000392	CcSEcCtD
Leflunomide—Anaphylactic shock—Prednisone—systemic lupus erythematosus	4.01e-05	0.000392	CcSEcCtD
Leflunomide—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	4e-05	0.000392	CcSEcCtD
Leflunomide—Decreased appetite—Betamethasone—systemic lupus erythematosus	4e-05	0.000392	CcSEcCtD
Leflunomide—Decreased appetite—Dexamethasone—systemic lupus erythematosus	4e-05	0.000392	CcSEcCtD
Leflunomide—Infection—Prednisone—systemic lupus erythematosus	3.98e-05	0.00039	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	3.97e-05	0.000389	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	3.97e-05	0.000389	CcSEcCtD
Leflunomide—Back pain—Methotrexate—systemic lupus erythematosus	3.97e-05	0.000389	CcSEcCtD
Leflunomide—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	3.97e-05	0.000388	CcSEcCtD
Leflunomide—Fatigue—Dexamethasone—systemic lupus erythematosus	3.97e-05	0.000388	CcSEcCtD
Leflunomide—Fatigue—Betamethasone—systemic lupus erythematosus	3.97e-05	0.000388	CcSEcCtD
Leflunomide—Pain—Dexamethasone—systemic lupus erythematosus	3.94e-05	0.000385	CcSEcCtD
Leflunomide—Pain—Betamethasone—systemic lupus erythematosus	3.94e-05	0.000385	CcSEcCtD
Leflunomide—Nervous system disorder—Prednisone—systemic lupus erythematosus	3.93e-05	0.000385	CcSEcCtD
Leflunomide—Tachycardia—Prednisone—systemic lupus erythematosus	3.91e-05	0.000383	CcSEcCtD
Leflunomide—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	3.91e-05	0.000383	CcSEcCtD
Leflunomide—PTK2B—Immune System—NCF2—systemic lupus erythematosus	3.91e-05	0.00103	CbGpPWpGaD
Leflunomide—Skin disorder—Prednisone—systemic lupus erythematosus	3.89e-05	0.000381	CcSEcCtD
Leflunomide—PTK2B—Immune System—LYN—systemic lupus erythematosus	3.88e-05	0.00102	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Prednisone—systemic lupus erythematosus	3.87e-05	0.000379	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—systemic lupus erythematosus	3.87e-05	0.000379	CcSEcCtD
Leflunomide—Asthenia—Hydrocortisone—systemic lupus erythematosus	3.86e-05	0.000378	CcSEcCtD
Leflunomide—Vomiting—Cyclosporine—systemic lupus erythematosus	3.85e-05	0.000377	CcSEcCtD
Leflunomide—PTK2B—Immune System—FCGR2A—systemic lupus erythematosus	3.83e-05	0.00101	CbGpPWpGaD
Leflunomide—Rash—Cyclosporine—systemic lupus erythematosus	3.82e-05	0.000374	CcSEcCtD
Leflunomide—Anorexia—Prednisone—systemic lupus erythematosus	3.82e-05	0.000374	CcSEcCtD
Leflunomide—Dermatitis—Cyclosporine—systemic lupus erythematosus	3.82e-05	0.000374	CcSEcCtD
Leflunomide—Pruritus—Hydrocortisone—systemic lupus erythematosus	3.81e-05	0.000373	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	3.81e-05	0.000373	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	3.8e-05	0.001	CbGpPWpGaD
Leflunomide—Headache—Cyclosporine—systemic lupus erythematosus	3.8e-05	0.000372	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—systemic lupus erythematosus	3.79e-05	0.000371	CcSEcCtD
Leflunomide—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	3.79e-05	0.000371	CcSEcCtD
Leflunomide—Feeling abnormal—Betamethasone—systemic lupus erythematosus	3.79e-05	0.000371	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—systemic lupus erythematosus	3.79e-05	0.000998	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PPARG—systemic lupus erythematosus	3.77e-05	0.000993	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	3.76e-05	0.000368	CcSEcCtD
Leflunomide—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	3.76e-05	0.000368	CcSEcCtD
Leflunomide—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	3.76e-05	0.000368	CcSEcCtD
Leflunomide—PTK2B—Immune System—TNFAIP3—systemic lupus erythematosus	3.76e-05	0.000991	CbGpPWpGaD
Leflunomide—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	3.74e-05	0.000366	CcSEcCtD
Leflunomide—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	3.73e-05	0.000365	CcSEcCtD
Leflunomide—Rash—Mycophenolate mofetil—systemic lupus erythematosus	3.73e-05	0.000365	CcSEcCtD
Leflunomide—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	3.72e-05	0.000365	CcSEcCtD
Leflunomide—PTK2B—Immune System—BLK—systemic lupus erythematosus	3.71e-05	0.000979	CbGpPWpGaD
Leflunomide—Headache—Mycophenolate mofetil—systemic lupus erythematosus	3.7e-05	0.000363	CcSEcCtD
Leflunomide—Malaise—Methotrexate—systemic lupus erythematosus	3.7e-05	0.000362	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—systemic lupus erythematosus	3.69e-05	0.000361	CcSEcCtD
Leflunomide—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	3.69e-05	0.000361	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—systemic lupus erythematosus	3.67e-05	0.00036	CcSEcCtD
Leflunomide—Urticaria—Dexamethasone—systemic lupus erythematosus	3.66e-05	0.000358	CcSEcCtD
Leflunomide—Urticaria—Betamethasone—systemic lupus erythematosus	3.66e-05	0.000358	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	3.65e-05	0.000357	CcSEcCtD
Leflunomide—Dizziness—Prednisolone—systemic lupus erythematosus	3.65e-05	0.000357	CcSEcCtD
Leflunomide—Asthenia—Triamcinolone—systemic lupus erythematosus	3.64e-05	0.000356	CcSEcCtD
Leflunomide—Body temperature increased—Betamethasone—systemic lupus erythematosus	3.64e-05	0.000356	CcSEcCtD
Leflunomide—Abdominal pain—Dexamethasone—systemic lupus erythematosus	3.64e-05	0.000356	CcSEcCtD
Leflunomide—Body temperature increased—Dexamethasone—systemic lupus erythematosus	3.64e-05	0.000356	CcSEcCtD
Leflunomide—Abdominal pain—Betamethasone—systemic lupus erythematosus	3.64e-05	0.000356	CcSEcCtD
Leflunomide—Asthenia—Methylprednisolone—systemic lupus erythematosus	3.63e-05	0.000355	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	3.63e-05	0.000956	CbGpPWpGaD
Leflunomide—Insomnia—Prednisone—systemic lupus erythematosus	3.62e-05	0.000355	CcSEcCtD
Leflunomide—Nausea—Cyclosporine—systemic lupus erythematosus	3.6e-05	0.000352	CcSEcCtD
Leflunomide—Paraesthesia—Prednisone—systemic lupus erythematosus	3.6e-05	0.000352	CcSEcCtD
Leflunomide—Pruritus—Triamcinolone—systemic lupus erythematosus	3.59e-05	0.000351	CcSEcCtD
Leflunomide—Cough—Methotrexate—systemic lupus erythematosus	3.58e-05	0.00035	CcSEcCtD
Leflunomide—Pruritus—Methylprednisolone—systemic lupus erythematosus	3.58e-05	0.00035	CcSEcCtD
Leflunomide—Dizziness—Hydrocortisone—systemic lupus erythematosus	3.56e-05	0.000349	CcSEcCtD
Leflunomide—Dyspepsia—Prednisone—systemic lupus erythematosus	3.53e-05	0.000345	CcSEcCtD
Leflunomide—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	3.51e-05	0.000344	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—systemic lupus erythematosus	3.49e-05	0.000342	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—systemic lupus erythematosus	3.49e-05	0.000342	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—systemic lupus erythematosus	3.49e-05	0.000342	CcSEcCtD
Leflunomide—Decreased appetite—Prednisone—systemic lupus erythematosus	3.48e-05	0.000341	CcSEcCtD
Leflunomide—Rash—Prednisolone—systemic lupus erythematosus	3.48e-05	0.00034	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—systemic lupus erythematosus	3.48e-05	0.000916	CbGpPWpGaD
Leflunomide—Dermatitis—Prednisolone—systemic lupus erythematosus	3.47e-05	0.00034	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	3.47e-05	0.00034	CcSEcCtD
Leflunomide—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	3.46e-05	0.000339	CcSEcCtD
Leflunomide—Fatigue—Prednisone—systemic lupus erythematosus	3.46e-05	0.000338	CcSEcCtD
Leflunomide—Headache—Prednisolone—systemic lupus erythematosus	3.46e-05	0.000338	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—systemic lupus erythematosus	3.45e-05	0.000338	CcSEcCtD
Leflunomide—Constipation—Prednisone—systemic lupus erythematosus	3.43e-05	0.000335	CcSEcCtD
Leflunomide—Vomiting—Hydrocortisone—systemic lupus erythematosus	3.42e-05	0.000335	CcSEcCtD
Leflunomide—Rash—Hydrocortisone—systemic lupus erythematosus	3.4e-05	0.000332	CcSEcCtD
Leflunomide—Dermatitis—Hydrocortisone—systemic lupus erythematosus	3.39e-05	0.000332	CcSEcCtD
Leflunomide—DHODH—Metabolism—ALB—systemic lupus erythematosus	3.39e-05	0.000893	CbGpPWpGaD
Leflunomide—Headache—Hydrocortisone—systemic lupus erythematosus	3.37e-05	0.00033	CcSEcCtD
Leflunomide—Dizziness—Triamcinolone—systemic lupus erythematosus	3.35e-05	0.000328	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	3.35e-05	0.000328	CcSEcCtD
Leflunomide—Dizziness—Methylprednisolone—systemic lupus erythematosus	3.35e-05	0.000328	CcSEcCtD
Leflunomide—Infection—Methotrexate—systemic lupus erythematosus	3.33e-05	0.000326	CcSEcCtD
Leflunomide—PTK2B—Immune System—PTPRC—systemic lupus erythematosus	3.32e-05	0.000875	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1RN—systemic lupus erythematosus	3.31e-05	0.000871	CbGpPWpGaD
Leflunomide—Feeling abnormal—Prednisone—systemic lupus erythematosus	3.3e-05	0.000323	CcSEcCtD
Leflunomide—Asthenia—Dexamethasone—systemic lupus erythematosus	3.3e-05	0.000323	CcSEcCtD
Leflunomide—Asthenia—Betamethasone—systemic lupus erythematosus	3.3e-05	0.000323	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	3.29e-05	0.000868	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	3.29e-05	0.000868	CbGpPWpGaD
Leflunomide—Nervous system disorder—Methotrexate—systemic lupus erythematosus	3.28e-05	0.000321	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	3.28e-05	0.000321	CcSEcCtD
Leflunomide—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	3.28e-05	0.000321	CcSEcCtD
Leflunomide—Nausea—Prednisolone—systemic lupus erythematosus	3.28e-05	0.000321	CcSEcCtD
Leflunomide—Pruritus—Dexamethasone—systemic lupus erythematosus	3.26e-05	0.000319	CcSEcCtD
Leflunomide—Pruritus—Betamethasone—systemic lupus erythematosus	3.26e-05	0.000319	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—systemic lupus erythematosus	3.25e-05	0.000318	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	3.25e-05	0.000857	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NOS3—systemic lupus erythematosus	3.24e-05	0.000854	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	3.24e-05	0.000317	CcSEcCtD
Leflunomide—Vomiting—Triamcinolone—systemic lupus erythematosus	3.22e-05	0.000316	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	3.22e-05	0.000849	CbGpPWpGaD
Leflunomide—Vomiting—Methylprednisolone—systemic lupus erythematosus	3.22e-05	0.000315	CcSEcCtD
Leflunomide—Nausea—Hydrocortisone—systemic lupus erythematosus	3.2e-05	0.000313	CcSEcCtD
Leflunomide—Rash—Triamcinolone—systemic lupus erythematosus	3.2e-05	0.000313	CcSEcCtD
Leflunomide—Dermatitis—Triamcinolone—systemic lupus erythematosus	3.19e-05	0.000313	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—systemic lupus erythematosus	3.19e-05	0.000312	CcSEcCtD
Leflunomide—Rash—Methylprednisolone—systemic lupus erythematosus	3.19e-05	0.000312	CcSEcCtD
Leflunomide—Dermatitis—Methylprednisolone—systemic lupus erythematosus	3.19e-05	0.000312	CcSEcCtD
Leflunomide—Urticaria—Prednisone—systemic lupus erythematosus	3.18e-05	0.000312	CcSEcCtD
Leflunomide—Headache—Triamcinolone—systemic lupus erythematosus	3.18e-05	0.000311	CcSEcCtD
Leflunomide—Headache—Methylprednisolone—systemic lupus erythematosus	3.17e-05	0.00031	CcSEcCtD
Leflunomide—Abdominal pain—Prednisone—systemic lupus erythematosus	3.17e-05	0.00031	CcSEcCtD
Leflunomide—Body temperature increased—Prednisone—systemic lupus erythematosus	3.17e-05	0.00031	CcSEcCtD
Leflunomide—Diarrhoea—Betamethasone—systemic lupus erythematosus	3.15e-05	0.000308	CcSEcCtD
Leflunomide—Diarrhoea—Dexamethasone—systemic lupus erythematosus	3.15e-05	0.000308	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—systemic lupus erythematosus	3.13e-05	0.000306	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—TLR9—systemic lupus erythematosus	3.1e-05	0.000816	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD40—systemic lupus erythematosus	3.09e-05	0.000814	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	3.05e-05	0.000299	CcSEcCtD
Leflunomide—Dizziness—Dexamethasone—systemic lupus erythematosus	3.04e-05	0.000298	CcSEcCtD
Leflunomide—Dizziness—Betamethasone—systemic lupus erythematosus	3.04e-05	0.000298	CcSEcCtD
Leflunomide—PTK2B—Immune System—HMGB1—systemic lupus erythematosus	3.04e-05	0.000802	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTLA4—systemic lupus erythematosus	3.04e-05	0.000802	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	3.04e-05	0.000801	CbGpPWpGaD
Leflunomide—Insomnia—Methotrexate—systemic lupus erythematosus	3.03e-05	0.000296	CcSEcCtD
Leflunomide—Nausea—Triamcinolone—systemic lupus erythematosus	3.01e-05	0.000295	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—systemic lupus erythematosus	3.01e-05	0.000294	CcSEcCtD
Leflunomide—Nausea—Methylprednisolone—systemic lupus erythematosus	3.01e-05	0.000294	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—P2RY12—systemic lupus erythematosus	3e-05	0.000791	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNA1—systemic lupus erythematosus	2.99e-05	0.000788	CbGpPWpGaD
Leflunomide—Dyspnoea—Methotrexate—systemic lupus erythematosus	2.99e-05	0.000292	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTGS2—systemic lupus erythematosus	2.96e-05	0.000781	CbGpPWpGaD
Leflunomide—Hypersensitivity—Prednisone—systemic lupus erythematosus	2.95e-05	0.000289	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—systemic lupus erythematosus	2.95e-05	0.000289	CcSEcCtD
Leflunomide—Vomiting—Betamethasone—systemic lupus erythematosus	2.93e-05	0.000286	CcSEcCtD
Leflunomide—Vomiting—Dexamethasone—systemic lupus erythematosus	2.93e-05	0.000286	CcSEcCtD
Leflunomide—PTK2B—Immune System—RASGRP1—systemic lupus erythematosus	2.91e-05	0.000768	CbGpPWpGaD
Leflunomide—Decreased appetite—Methotrexate—systemic lupus erythematosus	2.91e-05	0.000285	CcSEcCtD
Leflunomide—PTK2B—Immune System—CD79A—systemic lupus erythematosus	2.9e-05	0.000765	CbGpPWpGaD
Leflunomide—Rash—Dexamethasone—systemic lupus erythematosus	2.9e-05	0.000284	CcSEcCtD
Leflunomide—Rash—Betamethasone—systemic lupus erythematosus	2.9e-05	0.000284	CcSEcCtD
Leflunomide—Dermatitis—Betamethasone—systemic lupus erythematosus	2.9e-05	0.000284	CcSEcCtD
Leflunomide—Dermatitis—Dexamethasone—systemic lupus erythematosus	2.9e-05	0.000284	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	2.89e-05	0.000283	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	2.89e-05	0.000762	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	2.89e-05	0.000762	CbGpPWpGaD
Leflunomide—Fatigue—Methotrexate—systemic lupus erythematosus	2.89e-05	0.000283	CcSEcCtD
Leflunomide—Headache—Dexamethasone—systemic lupus erythematosus	2.88e-05	0.000282	CcSEcCtD
Leflunomide—Headache—Betamethasone—systemic lupus erythematosus	2.88e-05	0.000282	CcSEcCtD
Leflunomide—Asthenia—Prednisone—systemic lupus erythematosus	2.88e-05	0.000281	CcSEcCtD
Leflunomide—Pain—Methotrexate—systemic lupus erythematosus	2.86e-05	0.00028	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—RXRA—systemic lupus erythematosus	2.85e-05	0.000752	CbGpPWpGaD
Leflunomide—Pruritus—Prednisone—systemic lupus erythematosus	2.84e-05	0.000278	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	2.83e-05	0.000747	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PRL—systemic lupus erythematosus	2.82e-05	0.000744	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CSK—systemic lupus erythematosus	2.76e-05	0.000728	CbGpPWpGaD
Leflunomide—Feeling abnormal—Methotrexate—systemic lupus erythematosus	2.76e-05	0.00027	CcSEcCtD
Leflunomide—Diarrhoea—Prednisone—systemic lupus erythematosus	2.74e-05	0.000268	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	2.74e-05	0.000268	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	2.74e-05	0.000722	CbGpPWpGaD
Leflunomide—Nausea—Betamethasone—systemic lupus erythematosus	2.73e-05	0.000268	CcSEcCtD
Leflunomide—Nausea—Dexamethasone—systemic lupus erythematosus	2.73e-05	0.000268	CcSEcCtD
Leflunomide—PTK2B—Immune System—HLA-DQA1—systemic lupus erythematosus	2.68e-05	0.000706	CbGpPWpGaD
Leflunomide—Urticaria—Methotrexate—systemic lupus erythematosus	2.66e-05	0.00026	CcSEcCtD
Leflunomide—Dizziness—Prednisone—systemic lupus erythematosus	2.65e-05	0.000259	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—systemic lupus erythematosus	2.65e-05	0.000259	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—systemic lupus erythematosus	2.65e-05	0.000259	CcSEcCtD
Leflunomide—Vomiting—Prednisone—systemic lupus erythematosus	2.55e-05	0.000249	CcSEcCtD
Leflunomide—Rash—Prednisone—systemic lupus erythematosus	2.53e-05	0.000247	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—NCF2—systemic lupus erythematosus	2.52e-05	0.000666	CbGpPWpGaD
Leflunomide—Dermatitis—Prednisone—systemic lupus erythematosus	2.52e-05	0.000247	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	2.51e-05	0.000662	CbGpPWpGaD
Leflunomide—Headache—Prednisone—systemic lupus erythematosus	2.51e-05	0.000246	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—LYN—systemic lupus erythematosus	2.51e-05	0.000661	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DQB1—systemic lupus erythematosus	2.51e-05	0.00066	CbGpPWpGaD
Leflunomide—Hypersensitivity—Methotrexate—systemic lupus erythematosus	2.47e-05	0.000242	CcSEcCtD
Leflunomide—DHODH—Metabolism—EP300—systemic lupus erythematosus	2.47e-05	0.00065	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SH2B3—systemic lupus erythematosus	2.46e-05	0.000649	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—RXRA—systemic lupus erythematosus	2.44e-05	0.000642	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—systemic lupus erythematosus	2.4e-05	0.000235	CcSEcCtD
Leflunomide—Nausea—Prednisone—systemic lupus erythematosus	2.38e-05	0.000233	CcSEcCtD
Leflunomide—PTK2B—Immune System—IL18—systemic lupus erythematosus	2.38e-05	0.000626	CbGpPWpGaD
Leflunomide—Pruritus—Methotrexate—systemic lupus erythematosus	2.37e-05	0.000232	CcSEcCtD
Leflunomide—PTK2B—Immune System—CD40LG—systemic lupus erythematosus	2.37e-05	0.000624	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	2.35e-05	0.000619	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	2.35e-05	0.000619	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—systemic lupus erythematosus	2.34e-05	0.000617	CbGpPWpGaD
Leflunomide—Diarrhoea—Methotrexate—systemic lupus erythematosus	2.29e-05	0.000224	CcSEcCtD
Leflunomide—PTK2B—Immune System—JAK1—systemic lupus erythematosus	2.26e-05	0.000595	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—systemic lupus erythematosus	2.22e-05	0.000587	CbGpPWpGaD
Leflunomide—Dizziness—Methotrexate—systemic lupus erythematosus	2.21e-05	0.000217	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—systemic lupus erythematosus	2.13e-05	0.000208	CcSEcCtD
Leflunomide—Rash—Methotrexate—systemic lupus erythematosus	2.11e-05	0.000207	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—systemic lupus erythematosus	2.11e-05	0.000206	CcSEcCtD
Leflunomide—PTK2B—Immune System—IL2RA—systemic lupus erythematosus	2.11e-05	0.000556	CbGpPWpGaD
Leflunomide—Headache—Methotrexate—systemic lupus erythematosus	2.1e-05	0.000205	CcSEcCtD
Leflunomide—PTK2B—Immune System—C3—systemic lupus erythematosus	2.09e-05	0.000551	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	2.06e-05	0.000543	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL12—systemic lupus erythematosus	2.02e-05	0.000532	CbGpPWpGaD
Leflunomide—Nausea—Methotrexate—systemic lupus erythematosus	1.99e-05	0.000195	CcSEcCtD
Leflunomide—PTK2B—Immune System—CRP—systemic lupus erythematosus	1.99e-05	0.000524	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUNB—systemic lupus erythematosus	1.98e-05	0.000522	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—systemic lupus erythematosus	1.91e-05	0.000503	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DRB1—systemic lupus erythematosus	1.91e-05	0.000502	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.88e-05	0.000496	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PRL—systemic lupus erythematosus	1.83e-05	0.000481	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD80—systemic lupus erythematosus	1.76e-05	0.000464	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NAT2—systemic lupus erythematosus	1.72e-05	0.000454	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TYK2—systemic lupus erythematosus	1.49e-05	0.000392	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JAK1—systemic lupus erythematosus	1.46e-05	0.000385	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNG—systemic lupus erythematosus	1.39e-05	0.000367	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCR5—systemic lupus erythematosus	1.38e-05	0.000365	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.36e-05	0.000359	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—C3—systemic lupus erythematosus	1.35e-05	0.000356	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—systemic lupus erythematosus	1.34e-05	0.000354	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—systemic lupus erythematosus	1.26e-05	0.000333	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—systemic lupus erythematosus	1.24e-05	0.000326	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—F2—systemic lupus erythematosus	1.19e-05	0.000313	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.17e-05	0.000308	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—systemic lupus erythematosus	1.17e-05	0.000307	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD80—systemic lupus erythematosus	1.14e-05	0.0003	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—systemic lupus erythematosus	1.11e-05	0.000292	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.09e-05	0.000289	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL2—systemic lupus erythematosus	1.06e-05	0.000279	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RXRA—systemic lupus erythematosus	9.65e-06	0.000254	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TYK2—systemic lupus erythematosus	9.61e-06	0.000253	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOS3—systemic lupus erythematosus	9.43e-06	0.000249	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	9.36e-06	0.000247	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAT2—systemic lupus erythematosus	8.7e-06	0.000229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—systemic lupus erythematosus	8.17e-06	0.000215	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—systemic lupus erythematosus	7.99e-06	0.000211	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—systemic lupus erythematosus	7.57e-06	0.000199	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—systemic lupus erythematosus	7.54e-06	0.000199	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAT2—systemic lupus erythematosus	7.43e-06	0.000196	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—systemic lupus erythematosus	7.27e-06	0.000192	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—systemic lupus erythematosus	7.17e-06	0.000189	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	6.91e-06	0.000182	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—systemic lupus erythematosus	6.79e-06	0.000179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—systemic lupus erythematosus	6.23e-06	0.000164	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	6.22e-06	0.000164	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—systemic lupus erythematosus	6.1e-06	0.000161	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.91e-06	0.000156	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—systemic lupus erythematosus	5.48e-06	0.000144	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	5.44e-06	0.000143	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	5.31e-06	0.00014	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NOS3—systemic lupus erythematosus	5.24e-06	0.000138	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	4.88e-06	0.000129	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—systemic lupus erythematosus	4.79e-06	0.000126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—systemic lupus erythematosus	4.7e-06	0.000124	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.65e-06	0.000122	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	4.52e-06	0.000119	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	4.17e-06	0.00011	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—systemic lupus erythematosus	3.99e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.86e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	3.08e-06	8.12e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	2.77e-06	7.3e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	2.65e-06	6.98e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	2.63e-06	6.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	2.42e-06	6.38e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	2.37e-06	6.24e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	2.26e-06	5.96e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	2.07e-06	5.46e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	2.01e-06	5.31e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	1.72e-06	4.54e-05	CbGpPWpGaD
